Nektar details new REZOLVE-AD Phase 2b trial data

Nektar Therapeutics filed a current report describing new clinical data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin in atopic dermatitis.

Rhea-AI Filing Summary

Nektar Therapeutics filed a current report describing new clinical data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin in atopic dermatitis. The company posted a slide deck on its website with additional efficacy and safety information and furnished it as Exhibit 99.1. Nektar also issued a press release about the new data and a late-breaker oral presentation at EADV 2025, furnished as Exhibit 99.2. These materials are being furnished, not filed, which limits their use under certain securities law provisions.

Insights

Biotech and clinical-trials analyst

Nektar highlights new Phase 2b atopic dermatitis data via slides and a press release.

Nektar Therapeutics is drawing attention to new results from the REZOLVE-AD Phase 2b trial of rezpegaldesleukin in atopic dermatitis. The company furnished an investor slide deck and a press release summarizing final 16-week induction data and noted that the findings were presented as a late-breaker oral session at EADV 2025. This positioning suggests the dataset is important to its development narrative, even though the excerpt does not detail specific outcomes.

The information is furnished rather than filed, which is a common approach for scientific and investor materials and affects how the content is treated under Section 18 of the Exchange Act. Future investor focus will likely center on the detailed efficacy and safety metrics in the attached slides and how these Phase 2b results might inform any subsequent Phase 3 planning that the company may disclose in later communications.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nektar Therapeutics (NKTR) disclose in this 8-K filing?

Nektar Therapeutics disclosed that it has shared new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin in atopic dermatitis, supported by a slide deck (Exhibit 99.1) and a press release (Exhibit 99.2).

What is the REZOLVE-AD Phase 2b study mentioned by Nektar (NKTR)?

REZOLVE-AD is a Phase 2b study evaluating rezpegaldesleukin, described as a selective regulatory T-cell-inducing interleukin-2 conjugate, for the treatment of atopic dermatitis, with final 16-week induction results featured in the slides.

How is Nektar sharing the new REZOLVE-AD Phase 2b data with investors?

Nektar posted slides on its website with additional information on the REZOLVE-AD Phase 2b data and attached the deck as Exhibit 99.1, along with a press release as Exhibit 99.2 summarizing the new findings.

Are the REZOLVE-AD materials considered filed or furnished by Nektar?

The company states that the information under Item 7.01, including Exhibit 99.1, is being furnished and not filed for purposes of Section 18 of the Securities Exchange Act of 1934.

What scientific meeting is associated with Nektar’s new rezpegaldesleukin data?

The press release titled “Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025” indicates the data were featured at that dermatology congress.

Does the Nektar (NKTR) 8-K incorporate content from its website?

Nektar notes that while slides are posted on www.nektar.com, information on the website is not incorporated by reference into this report and should not be considered part of it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/18/2025 - 08:56 AM Learn about SEC filing dates

false 0000906709 0000906709 2025-09-18 2025-09-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 18, 2025

NEKTAR THERAPEUTICS

(Exact Name of Registrant as Specified in Charter)

Delaware		0-24006		94-3134940
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

455 Mission Bay Boulevard South

San Francisco, California 94158

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (415) 482-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		NKTR		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 18, 2025, Nektar Therapeutics (“Nektar”) posted slides on its website (www.nektar.com) containing additional information related to certain new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, as discussed in Item 8.01 below. A copy of the slides is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Information contained on Nektar’s website is not incorporated by reference into this Current Report on Form 8-K, and you should not consider any information on, or that can be accessed from, Nektar’s website as part of this Current Report on Form 8-K.

The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Nektar undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.

Item 8.01 Other Events.

On September 18, 2025, Nektar announced certain new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin. A copy of the press release issued in connection with the announcement is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1		Slides Titled “Efficacy and Safety of Rezpegaldesleukin, A Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from the 16-Week Induction of a Randomized Phase 2b Study (REZOLVE AD)”.
99.2		Press Release Titled “Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025”.
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEKTAR THERAPEUTICS
Date: September 18, 2025	By:	/s/ Mark A. Wilson
		Mark A. Wilson
		Chief Legal Officer and Secretary

2